Outcome of 5-years active cardiological management of oncohematological patients on targeted therapy

Abstract Background The overall survival of oncohematological patients (pts) depends not only on the severity cancer, anticancer therapy used and comorbidity pts. most important role in management these pts is played by supervision a cardiologist. Purpose To assess effect active cardiac targeted with ibrutinib. Methods We examined observed dynamics for 5 years 217 chronic lymphocytic leukemia (CLL), constantly receiving ibrutinib, inducing arterial hypertension (AH) atrial fibrillation (AF) part All underwent echocardiography (Echo), 24-hour Holter ECG monitoring (HM), assessment using Charlson index screening fragility G8 questionnaire. Everyday measurement blood pressure, heart rate morning evening keeping diary was recommended all pts, but 89 were performed, who contacted us remotely instant messengers formed an (ACM) group. Results studied CLL depending monitoring, starting from first visit. age ACM group (n=89) other (n=138) did differ amounted to 66.0 (60.0–70.0) (59.0–74.0) respectively. number men women groups comparable. In group, there significantly more AH - 86.5% AF 42.7% compared 50.4% 15.9% rest (p<0.0001 both cases) comparable coronary artery disease. According HM, short episodes 31.4% versus 8.0% (p<0.0001). Accordingly, received cardiological treatment 87.6%, 53.6% Echo parameters groups. Indicators that affect general (Charlson index, scores questionnaire) CLL. also hematological status cases second tumors. At same time, despite pronounced comorbidity, under including continuous remote demonstrated better Conclusions Conducting management, constant observation, allows achieving higher rates cancer patients, severe periodic Funding Acknowledgement Type funding sources: Public Institution(s). Main source(s): no founding sources